Cited 0 times in Scipus Cited Count

Clinical features and treatment outcomes of Langerhans cell histiocytosis: a nationwide survey from Korea histiocytosis working party.

DC Field Value Language
dc.contributor.authorKoh, KN-
dc.contributor.authorSuh, JK-
dc.contributor.authorIm, HJ-
dc.contributor.authorSong, JS-
dc.contributor.authorLee, JW-
dc.contributor.authorKang, HJ-
dc.contributor.authorPark, KD-
dc.contributor.authorShin, HY-
dc.contributor.authorChoi, HS-
dc.contributor.authorLee, SH-
dc.contributor.authorYoo, KH-
dc.contributor.authorSung, KW-
dc.contributor.authorKoo, HH-
dc.contributor.authorJung, HL-
dc.contributor.authorCho, B-
dc.contributor.authorKim, HK-
dc.contributor.authorLyu, CJ-
dc.contributor.authorBaek, HJ-
dc.contributor.authorKook, H-
dc.contributor.authorPark, JE-
dc.contributor.authorPark, HJ-
dc.contributor.authorPark, BK-
dc.contributor.authorYoo, ES-
dc.contributor.authorRyu, KH-
dc.contributor.authorLee, KS-
dc.contributor.authorKim, HS-
dc.contributor.authorLee, JM-
dc.contributor.authorPark, ES-
dc.contributor.authorYoon, HS-
dc.contributor.authorLee, KC-
dc.contributor.authorLee, MJ-
dc.contributor.authorLim, YT-
dc.contributor.authorKim, HM-
dc.contributor.authorPark, SK-
dc.contributor.authorPark, JA-
dc.contributor.authorKim, SK-
dc.contributor.authorPark, M-
dc.contributor.authorLim, YJ-
dc.contributor.authorLee, YH-
dc.contributor.authorSeo, JJ-
dc.date.accessioned2016-10-17T04:59:41Z-
dc.date.available2016-10-17T04:59:41Z-
dc.date.issued2014-
dc.identifier.issn1077-4114-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/12654-
dc.description.abstractA nationwide survey was conducted to clarify the clinical features and outcomes

of Korean children with Langerhans cell histiocytosis (LCH). Korea Histiocytosis

Working Party analyzed the data of 603 patients who were diagnosed with LCH

between 1986 and 2010 from 28 institutions in Korea. Median age at diagnosis was

65 months (range, 0 to 276 mo). Bone was the most frequently affected organ

(79.6%) followed by skin (19.2%). Initially, 419 patients (69.5%) had

single-system involvement (SS), 85 (14.1%) with multisystem (MS) disease without

risk organ involvement (MS-RO), and 99 (16.4%) multisystem disease with risk

organ involvement (MS-RO). The 5-year overall survival (OS) rates in the SS,

MS-RO, and MS-RO groups were 99.8%, 98.4%, and 77.0%, respectively (P<0.001), and

the 5-year reactivation rates were 17.9%, 33.5%, and 34.3%, respectively

(P<0.001). The OS rate was lower in patients with RO involvement (P=0.025) and

lack of response to initial treatment (P=0.001). MS involvement (P=0.036) was an

independent risk factor for reactivation. Permanent consequences were documented

in 99 patients (16.4%). Reactivation of disease, MS involvement, and age at

diagnosis
consequences. This study emphasized that further efforts are required to improve

survival of MS-RO patients and reduce reactivation in younger patients with MS

involvement.
-
dc.language.isoen-
dc.subject.MESHChild, Preschool-
dc.subject.MESHData Collection-
dc.subject.MESHDemocratic People's Republic of Korea-
dc.subject.MESHHistiocytosis-
dc.subject.MESHInfant, Newborn-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHProportional Hazards Models-
dc.subject.MESHTreatment Outcome-
dc.titleClinical features and treatment outcomes of Langerhans cell histiocytosis: a nationwide survey from Korea histiocytosis working party.-
dc.typeArticle-
dc.identifier.pmid24276037-
dc.identifier.urlhttp://ovidsp.tx.ovid.com/sp-3.22.1b/ovidweb.cgi?QS2=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-
dc.contributor.affiliatedAuthor박, 준은-
dc.type.localJournal Papers-
dc.identifier.doi10.1097/MPH.0000000000000054-
dc.citation.titleJournal of pediatric hematology/oncology-
dc.citation.volume36-
dc.citation.number2-
dc.citation.date2014-
dc.citation.startPage125-
dc.citation.endPage133-
dc.identifier.bibliographicCitationJournal of pediatric hematology/oncology, 36(2). : 125-133, 2014-
dc.identifier.eissn1536-3678-
dc.relation.journalidJ010774114-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Pediatrics & Adolescent Medicine
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse